APPLICATION
ANDA079246
TYPE
ANDA
ORIGINAL APPROVAL
2016-09-29
LATEST ACTION
2023-06-21
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
ABACAVIR SULFATE AND LAMIVUDINEDiscontinued
ABACAVIR SULFATE EQ 600MG BASE, LAMIVUDINE 300MG · TABLET · ORAL
Approval history
2023-06-21Labeling · Supplement 11 · standardAP
2020-11-12Labeling · Supplement 6 · standardAP
2020-11-12Labeling · Supplement 4 · standardAP
2020-11-12Labeling · Supplement 9 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.